Jason V. Coloma, an officer at Maze Therapeutics, Inc., filed a Form 144 notice of proposed sale of 34,501 shares of common stock on November 2, 2026, through UBS Financial Services Inc. on the Nasdaq exchange.

Key Highlights

  • Proposed sale size: 34,501 shares of Maze Therapeutics common stock with an aggregate market value of $1,093,681.70, according to the filing.
  • Seller relationship: Jason V. Coloma is identified as an officer of the issuer, Maze Therapeutics, Inc.
  • Trust structures: 2,593 shares are held under The Coloma 2021 Irrevocable Trust DTD 09/20/2021 and 31,908 shares are held under the Coloma Family Trust DTD 06/27/2016.
  • Shares outstanding: The filing states 55,549,168 shares of common stock outstanding at the time of the notice.
  • Rule 10b5-1 plan: The filing indicates a trading plan or instruction date of February 6, 2026.
  • Approximate sale date: November 2, 2026, through broker UBS Financial Services Inc., Eleven Madison Avenue, 4th Floor, New York, NY 10010.

Coloma Trust Entities Plan Sale of Maze Therapeutics Common Stock Under Rule 144

According to the Form 144 filed with the SEC on November 2, 2026, Jason V. Coloma, an officer of Maze Therapeutics, Inc. (Nasdaq), intends to sell 34,501 shares of the company's common stock. The filing lists an aggregate market value of $1,093,681.70 for the proposed sale. The broker named in the filing is UBS Financial Services Inc., located at Eleven Madison Avenue, 4th Floor, New York, NY 10010. Maze Therapeutics is headquartered at 171 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080.

The shares to be sold were acquired as gifts. Specifically, 2,593 shares were gifted on September 22, 2021, from Jason Coloma, who originally acquired them on November 1, 2018. An additional 31,908 shares were also received as a gift on September 22, 2021, from Jason Coloma, who originally acquired those on June 24, 2019. Both lots are classified as common stock with no cash payment indicated, listed as "NA" in the nature of payment field.

The filing also discloses sales during the past three months by entities associated with Coloma. The Coloma 2021 Irrevocable Trust sold 2,593 shares on August 3, 2026 (gross proceeds $69,329.00), September 1, 2026 ($68,214.05), and October 1, 2026 ($70,073.49). The Coloma Family Trust sold 31,908 shares on August 3, 2026 (gross proceeds $852,983.80), September 1, 2026 ($838,784.74), and October 1, 2026 ($862,186.07). The filing notes that the proposed sale is being made pursuant to a Rule 10b5-1 plan adopted or instruction given on February 6, 2026, with UBS Financial Services Inc. signing as attorney-in-fact for Jason Coloma as trustee.

What Was Disclosed

A Form 144 notice was filed on November 2, 2026, disclosing Jason V. Coloma's intent to sell 34,501 shares of Maze Therapeutics common stock with an aggregate market value of $1,093,681.70, held across two trust entities, via UBS Financial Services Inc. on Nasdaq.